A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson’s disease.
Category: biotech/medical – Page 82
Landmark study investigates potential of Ambroxol, a cough medicine, to slow Parkinson’s-related dementia
LONDON, Ont. – Dementia poses a major health challenge with no safe, affordable treatments to slow its progression.
Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph’s Health Care London, are investigating whether Ambroxol — a cough medicine used safely for decades in Europe — can slow dementia in people with Parkinson’s disease.
Published today in the prestigious JAMA Neurology, this 12-month clinical trial involving 55 participants with Parkinson’s disease dementia (PDD) monitored memory, psychiatric symptoms and GFAP, a blood marker linked to brain damage.
Parkinson’s disease dementia causes memory loss, confusion, hallucinations and mood changes. About half of those diagnosed with Parkinson’s develop dementia within 10 years, profoundly affecting patients, families and the health care system.
Researchers develop novel antibody-RNA therapy for resistant cancers
A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models, according to a study reported in Science Translational Medicine.
The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy stubborn diseased cells in pancreatic, brain, and skin cancers.
“Delivery of RNA-based therapies to tumors has been a challenge. Our finding that TMAB3 can form antibody/RNA complexes capable of delivering RNA payloads to tumors provides a new approach to overcome this challenge,” says Peter Glazer, senior author and Robert E. Hunter Professor of Therapeutic Radiology and Genetics at Yale School of Medicine (YSM).
High-speed mapping of whole-mouse peripheral nerves
Early-onset gastrointestinal cancers, typically defined as cancer diagnosed in individuals younger than 50 years, are among the largest subset of early-onset cancers globally.
This JAMA Review summarizes current evidence on early-onset gastrointestinal cancers.
This Review summarizes current evidence on colorectal, pancreatic, and esophagogastric cancers among individuals aged 18 to 49 years.
Scientists discover a simple set of rules that may explain how the body’s tissues stay organized
Every day, your body replaces billions of cells—and yet, your tissues stay perfectly organized. How is that possible?
A team of researchers at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute and the University of Delaware believe they’ve found an answer.
In a study published in Biology of the Cell, they show that just five basic rules may explain how the body maintains the complex structure of tissues like those in the colon, for example, even as its cells are constantly dying and being replaced.
A Complete Human Genome Built from Scratch: This Unprecedented Scientific Feat Could Transform Everything We Know About Biology
IN A NUTSHELL 🌐 The SynHG project aims to synthesize a complete human genome, opening new horizons in biotechnology. ⚖️ Ethical considerations are central to the project, with a focus on responsible innovation and diverse cultural perspectives. 🧬 Initial steps involve creating a fully synthetic human chromosome, leveraging advances in synthetic biology and DNA chemistry.